STOCK TITAN

Vanda Pharma - VNDA STOCK NEWS

Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. (VNDA) is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies for conditions with high unmet medical needs. Employing state-of-the-art research and development (R&D) techniques, Vanda focuses on addressing complex medical conditions such as sleep-wake disorders, schizophrenia, bipolar disorder, and multiple sclerosis, among others. With a robust clinical pipeline and a deep commitment to scientific excellence, Vanda leverages advanced technologies, including antisense oligonucleotides (ASOs), to create targeted treatments that improve the quality of life for patients around the globe.

Core Business Areas and Therapeutic Focus

At its core, Vanda specializes in translating intricate scientific research into commercially viable therapies. The company has successfully commercialized products such as HETLIOZ, which is used for treating Non-24-Hour Sleep-Wake Disorder and nighttime disturbances in Smith-Magenis Syndrome patients, and Fanapt, which addresses psychiatric conditions including schizophrenia. Vanda further diversifies its portfolio with products like PONVORY, aiming to meet critical market needs in multiple sclerosis and other inflammatory conditions. The company’s dedication to uncovering and addressing overlooked therapeutic areas illustrates its commitment to improving patient outcomes in challenging clinical landscapes.

Research and Development Excellence

Vanda’s strong emphasis on R&D underpins its innovative approach to drug development. The company’s pipeline includes both late-stage and early-stage assets that tackle disorders with few effective treatment options. Its strategic approach involves rigorous clinical trials, state-of-the-art biomarker research, and adaptive study designs that ensure safety and efficacy. By incorporating industry-specific practices and leveraging advanced molecular and genetic technologies, Vanda has established itself as a trusted name in specialty pharmaceuticals.

Global Commercialization and Market Presence

Commercially, Vanda maintains a significant presence in key markets, predominantly in the United States but also extending its footprint across Europe, Canada, and Israel. The company has built an efficient commercial infrastructure designed to support its diverse product portfolio. This infrastructure not only facilitates the launch of novel therapies but also enables the effective management of a complex sales and marketing operation, ensuring that products reach the patients who need them most.

Competitive Landscape and Industry Position

Operating in the competitive field of specialty pharmaceuticals, Vanda differentiates itself through a combination of clinical innovation, strategic product positioning, and a focus on high unmet medical needs. Its product portfolio is backed by scientific research published in peer-reviewed journals and a series of well-controlled clinical studies. Vanda’s commitment to scientific transparency and adherence to regulatory standards reinforces its reputation as an authoritative and trustworthy entity in the biopharmaceutical industry.

Expertise, Experience, and Trustworthiness (E-E-A-T)

Vanda Pharmaceuticals exemplifies the E-E-A-T principles through its extensive history of clinical research, regulatory diligence, and targeted therapeutic development. The company’s ability to integrate scientific discovery with practical commercial strategy is evidenced by its ongoing engagement in critical clinical trials and strategic partnerships. Investors and healthcare professionals alike recognize Vanda for its thoughtful approach to innovation, its proven expertise in navigating complex regulatory environments, and its commitment to advancing therapies that address significant unmet patient needs.

Conclusion

Overall, Vanda Pharmaceuticals Inc. stands as a highly specialized biopharmaceutical company that combines rigorous scientific research with a comprehensive commercialization strategy. Its focus on complex, high-need therapeutic areas, coupled with innovation in drug development and a strong global presence, positions the company as a key player in the specialty pharmaceuticals arena.

Rhea-AI Summary

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation at Digestive Disease Week (DDW) 2022, taking place from May 21-24 in San Diego, CA. The company will present two significant studies by Dr. Sandra Paulina Smieszek, Head of Genetics. The first presentation on May 21 focuses on macrophage polarization in gastroparesis, while the second on May 23 discusses the gene set enrichment analysis in Ehlers Danlos syndrome patients with gastroparesis. For more details, visit DDW's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) reported a net loss of $6.4 million for Q1 2022, a significant shift from a net income of $8.7 million in Q1 2021. Total net product sales decreased by 4% to $60.2 million, with HETLIOZ® sales down 6% to $37.0 million. The company is optimistic about expanding access to HETLIOZ® for Medicaid patients and completing the Fanapt® bipolar study by year-end. Financial guidance for 2022 is set at $240 to $280 million in total revenues, with a year-end cash expectation exceeding $440 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
-
Rhea-AI Summary

Vanda Pharmaceuticals (VNDA) will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. PT (7:00 p.m. ET) in Las Vegas, Nevada. The presentation will be available live on the company's website, and an archived version will be accessible for approximately 30 days following the event. Vanda focuses on developing innovative therapies to meet high unmet medical needs for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
none
Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call is scheduled for 4:30 PM ET on the same day to discuss the results and corporate activities. Investors can participate via phone or by accessing a live broadcast on Vanda's website. A replay will be available starting at 7:30 PM ET the same day until May 12, 2022. Vanda is focused on developing innovative therapies for unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
-
Rhea-AI Summary

Vanda Pharmaceuticals (VNDA) reported Q4 and full-year 2021 results, showcasing total net product sales of $68.0 million in Q4 and $268.7 million for the year, reflecting increases of 1% and 8%, respectively. HETLIOZ® sales were $44.1 million in Q4, while Fanapt® reached $24.0 million. Net income for Q4 decreased to $7.1 million from $8.2 million in Q4 2020, but annual net income rose to $33.2 million from $23.3 million. Vanda anticipates 2022 revenue guidance of $240 to $280 million. A Phase III study of tradipitant did not meet its primary endpoint, prompting further analysis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
-
Rhea-AI Summary

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is set to release its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. A conference call will occur at 4:30 PM ET on the same day, where management will discuss the results and corporate activities. Investors can participate by calling 1-866-688-9426 (domestic) or 1-409-216-0816 (international) using passcode 5373895. A replay of the call will be available from 7:30 PM ET the same day until March 2, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) announced disappointing results from the Phase III study of tradipitant for treating gastroparesis, as it failed to meet its primary endpoint on nausea reduction. However, exploratory analyses suggest that the drug may have significant benefits when accounting for certain patient factors. Tradipitant demonstrated a similar safety profile to placebo, with diarrhea as the most common side effect. Vanda plans further data analysis and intends to pursue regulatory submissions, emphasizing their commitment to addressing unmet medical needs in gastroparesis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.88%
Tags
none
-
Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) announced a License Agreement with MSN Pharmaceuticals and Impax Laboratories to resolve patent litigation over the generic version of its drug HETLIOZ (tasimelteon). The agreement allows MSN and Impax to market their version of HETLIOZ in the U.S. starting March 13, 2035, or July 27, 2035, if Vanda obtains pediatric exclusivity. The settlement includes a release of all claims from the litigation and is pending review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
-
Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in significant investor conferences this November, including the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, and the Jefferies 2021 London Healthcare Conference on November 18-19, 2021. A corporate presentation will be available at the Stifel conference, while an on-demand fireside chat will be accessible for the Jefferies event. Investors can access presentations via Vanda's website, with archived content available for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
Rhea-AI Summary

Vanda Pharmaceuticals (VNDA) reported strong financial growth in Q3 2021, with total product sales of $70.1 million, a 16% increase from $60.3 million in Q3 2020. HETLIOZ® sales rose 15% to $45.6 million, while Fanapt® sales climbed 18% to $24.5 million. Net income reached $7.8 million, up from $5.9 million year-over-year. However, Vanda revised its HETLIOZ® sales guidance downward due to escalating reimbursement challenges, now estimating $170 to $190 million for 2021. The company anticipates results from a pivotal Phase III study on tradipitant in gastroparesis by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.05%
Tags

FAQ

What is the current stock price of Vanda Pharma (VNDA)?

The current stock price of Vanda Pharma (VNDA) is $4.5 as of April 1, 2025.

What is the market cap of Vanda Pharma (VNDA)?

The market cap of Vanda Pharma (VNDA) is approximately 261.5M.

What is the primary focus of Vanda Pharmaceuticals?

Vanda Pharmaceuticals is focused on developing and commercializing innovative therapies for conditions with high unmet medical needs, including sleep-wake disorders, schizophrenia, and bipolar disorder.

What therapeutic areas does Vanda address?

The company targets several critical areas such as Non-24-Hour Sleep-Wake Disorder, psychiatric conditions, and inflammatory and neurological disorders, among others.

How does Vanda generate revenue?

The majority of Vanda's revenue is derived through the commercialization of specialty products, complemented by its robust research and development of novel therapeutic assets.

What distinguishes Vanda's approach in drug development?

Vanda employs cutting-edge R&D methods and advanced technologies, such as antisense oligonucleotides, to create targeted therapies that address complex medical challenges.

What role does clinical research play in Vanda’s business model?

Clinical research is central to Vanda's model, ensuring that its therapeutics are supported by rigorous clinical evidence and are aligned with regulatory standards.

How does Vanda maintain its competitive edge?

The company differentiates itself through a strong clinical pipeline, strategic global commercialization efforts, and a consistent commitment to addressing high unmet medical needs.

In which markets does Vanda operate?

Vanda has a significant commercial presence in the United States and extends its operations to strategic markets including Europe, Canada, and Israel.

How does Vanda demonstrate its expertise and trustworthiness?

Vanda builds trust through extensive clinical research, transparent communication of its scientific findings, adherence to regulatory standards, and strategic partnerships across the biopharmaceutical industry.
Vanda Pharma

Nasdaq:VNDA

VNDA Rankings

VNDA Stock Data

261.55M
55.65M
4.69%
76.38%
5.62%
Biotechnology
Pharmaceutical Preparations
Link
United States
WASHINGTON